---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-097100"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:57:14.200033+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics stockholders approve reverse stock split authorization up to 1-for-10

## Summary
- Reverse split proposal approved with 91,108,798 votes for, 873,917 against, 32,292 abstentions.
- Board may implement split at ratio between 1-for-3 and 1-for-10 at any time before Dec 15, 2024.
- Adjournment proposal also approved but was not needed; 91,306,235 votes for, 669,886 against.
- Approximately 82% of outstanding shares were represented at the Dec 15 special meeting.

## SEC filing metadata
- accession: 0001213900-23-097100
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023097100/0001213900-23-097100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023097100/ea190382-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-097100
- JSON: https://secwatch.observer/filing/0001213900-23-097100.json
- Plain text: https://secwatch.observer/filing/0001213900-23-097100.txt

## Key facts
- Shareholder Votes
  Jasper Therapeutics, Inc. shareholders approved Approve an amendment to the Certificate of Incorporation to effect a reverse stock split within a range of 1-for-3 to 1-for-10 at the 2023-12-15 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-12-15
  source text: On December 15, 2023, Jasper Therapeutics, Inc. (the “Company”) held a Special Meeting of Stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023097100/0001213900-23-097100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.